HK Stock Market Move | SINO BIOPHARM (01177) rose more than 3% with the completion of subject enrollment in Phase III clinical trial of Vituximab Bevacizumab "CLDN18.2 ADC".

SINO BIOPHARM (01177) rose by over 3%, closing at a 3.09% increase at HKD 6.68, with a trading volume of HKD 1.49 billion. In terms of news, on February 9th, SINO BIOPHARM announced that its wholly-owned subsidiary, LiXin Pharmaceutical Technology (Shanghai) Co., Ltd. (LiXin Pharmaceutical), is conducting a Phase III registration clinical trial (LM302-03-101) for the first-in-class innovative drug Vituximab (LM-302) "CLDN18.2 ADC" developed independently by LiXin Pharmaceutical, for the treatment of third-line or above CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma. The trial has successfully enrolled patients. LM302 is the world's first CLDN18.2 ADC drug to complete a Phase III registration clinical trial enrollment. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, LiXin Pharmaceutical presented the latest research data on the combination of LM-302 with Trastuzumab treatment for gastric cancer: among 41 evaluable patients, the objective response rate (ORR) was 65.9% and the disease control rate (DCR) was 85.4%. Among the 32 patients with CLDN18.2 expression 25%, the ORR was 71.9% and the DCR was 96.9%. In the stratified analysis by PD-L1 expression, the ORR for patients with PD-L1 CPS <1 was 63.3% and for those with CPS 1, the ORR was 77.8%. This study demonstrates that the LM302 combination therapy shows significant anti-tumor activity and manageable safety profile in CLDN18.2-positive patients.